Burden of EPS in Commercial Patients With Schizophrenia Initiating Atypical Antipsychotics
This study investigated the 1-year incidence of extrapyramidal symptoms (EPS), as well as the incremental economic burden, in patients with schizophrenia initiating atypical antipsychotics.